Search Within

Biostatistics Service

  1. "Clifford Hudis"
Formats
  1. Meeting Abstract (128)
  2. Journal Article (93)
Groups
  1. Breast Medicine Service (221)
  2. Department of Medicine (221)
  3. Epidemiology and Biostatistics (221)
  4. Solid Tumor Oncology Division (221)
  5. Survivorship Research (221)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (145)

More Groups

People
  1. Clifford Hudis (221)
  2. Sujata Patil (141)
  3. Larry Norton (127)
  4. Katherine Panageas (56)
  5. Maura Dickler (52)
  6. Chau Dang (48)

More People

Years
  1. 2020 (1)
  2. 2019 (2)
  3. 2018 (5)
  4. 2017 (8)
  5. 2016 (24)
  6. 2015 (20)

More Years

Publications
  1. Journal of Clinical Oncology (70)
  2. Cancer Research (36)
  3. Breast Cancer Research and Treatment (22)
  4. Cancer (17)
  5. Clinical Cancer Research (14)
  6. Clinical Breast Cancer (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (70)
  2. American Association for Cancer Research (54)
  3. Springer (26)
  4. Wiley Blackwell (22)
  5. Elsevier Inc. (16)
  6. Oxford University Press (10)

More Publishers

Results (221)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel and dasatinib in metastatic breast cancer
    Journal Article

    Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: An argument for earlier detection
    Journal Article

    Morikawa, A.; Wang, R.; Patil, S.; Diab, A.; Yang, J.; Hudis, C. A.; McArthur, H. L.; Beal, K.; Seidman, A. D.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • The genomic landscape of endocrine-resistant advanced breast cancers
    Journal Article

    Razavi, P.; Chang, M. T.; Xu, G.; Bandlamudi, C.; Ross, D. S.; Vasan, N.; Cai, Y.; Bielski, C. M.; Donoghue, M. T. A.; Jonsson, P.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Monosomy 17 in potentially curable HER2-amplified breast cancer: Prognostic and predictive impact
    Journal Article

    Page, D. B.; Wen, H.; Brogi, E.; Dure, D.; Ross, D.; Spinelli, K. J.; Patil, S.; Norton, L.; Hudis, C.; McArthur, H. L.
    Breast Cancer Research and Treatment (2018)

    Fulltext@MSK | Save
  • Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer
    Meeting Abstract

    Wang, R.; Yu, A. F.; Steingart, R.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C. T.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save